ArcticZymes Technologies ASA Q2 and 6 months 2023 results

Tromsø, Norway, 17th August 2023 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 28.2 million and an EBITDA of NOK 6.8 million for the second quarter of 2023. Highlights from Q2 and 6 months 2023 ArcticZymes Technologies (AZT) had Q2 sales of NOK 28.2 million (Q2 2022: NOK 30.4 million) and sales for the first 6 months of NOK …

ArcticZymes Technologies launches AZtaqâ„¢ DNA Polymerase

Tromsø, Norway, 10 August 2023 – ArcticZymes Technologies ASA (OSE: AZT) launches AZtaqâ„¢ DNA Polymerase. ArcticZymes Technologies (AZT) today announces the launch of its new product, AZtaqâ„¢ DNA Polymerase. AZtaqâ„¢ is a high-quality thermostable DNA polymerase suitable for use in polymerase chain reaction (PCR) applications. Launching the AZtaqâ„¢ is a natural expansion of the Company’s molecular tools portfolio. Being an …

ArcticZymes Technologies has filed DMF for SAN HQ GMP

Tromsø, Norway, June 29th 2023 – ArcticZymes Technologies ASA (OSE:AZT) announces the filing of a Drug Master File (DMF) to the US Food and Drug Administration (FDA) for Salt Active Nuclease High Quality GMP Grade (SAN HQ GMP). ArcticZymes is pleased to announce the filing of a DMF (Type II) for SAN HQ GMP with the US FDA’s Center for …

Notice of Annual General Meeting

The annual general meeting (“AGM”) in ArcticZymes Technologies ASA will be held on Tuesday 06. June 2023 at 12.00 CET. The meeting will be held as a virtual meeting, with an option for shareholders to participate digitally. Please click HERE for the notice and appendicies Shareholders who wish to attend the AGM, in person, electronically or by proxy, are requested to …